A phase 3 multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aducanumab (BIIB037) in subjects with early Alzheimer's Disease (2015–2019)
- Grant type:
- Biogen Australia
- Researchers:
-
-
Mayne Professor of Psychiatry
Medical School (Office & AME)Faculty of Medicine
-
- Funded by:
- Biogen Australia Pty Ltd
